{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:30:08Z","timestamp":1788366608552,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ijcard.2016.12.140","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T00:02:43Z","timestamp":1482883363000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Galectin-3 is an independent predictor of survival in systemic sclerosis"],"prefix":"10.1016","volume":"233","author":[{"given":"R\u00e9ka","family":"Faludi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"T\u0151k\u00e9s-F\u00fczesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Czirj\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Kom\u00f3csi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ijcard.2016.12.140_bb0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2016.12.140_bb0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00281-015-0506-4","article-title":"Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment","volume":"37","author":"Affandi","year":"2015","journal-title":"Semin. Immunopathol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.12.140_bb0015","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.114.218370","article-title":"Functions of galectin-3 and its role in fibrotic diseases","volume":"351","author":"Li","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.ijcard.2016.12.140_bb0020","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1084\/jem.20090121","article-title":"Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response","volume":"207","author":"Markowska","year":"2010","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2016.12.140_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10067-013-2346-8","article-title":"Serum galectin-3 level in systemic sclerosis","volume":"33","author":"Koca","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.12.140_bb0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.110755","article-title":"Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis","volume":"39","author":"Taniguchi","year":"2012","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.ijcard.2016.12.140_bb0035","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1136\/ard.2008.098087","article-title":"N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?","volume":"68","author":"Allanore","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"3 Suppl. 54","key":"10.1016\/j.ijcard.2016.12.140_bb0040","first-page":"59","article-title":"N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis","volume":"27","author":"Allanore","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6 Suppl. 86","key":"10.1016\/j.ijcard.2016.12.140_bb0045","article-title":"Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: a single centre study","volume":"32","author":"Kolto","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ijcard.2016.12.140_bb0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijcard.2016.08.246","article-title":"N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis","volume":"223","author":"Allanore","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.12.140_bb0055","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."},{"issue":"11","key":"10.1016\/j.ijcard.2016.12.140_bb0060","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.ijcard.2016.12.140_bb0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"1","key":"10.1016\/j.ijcard.2016.12.140_bb0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2016.12.140_bb0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","article-title":"The regulation of inflammation by galectin-3","volume":"230","author":"Henderson","year":"2009","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.ijcard.2016.12.140_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2332\/allergolint.O-06-449","article-title":"Role of galectin-3 in human pulmonary fibrosis","volume":"56","author":"Nishi","year":"2007","journal-title":"Allergol. Int."},{"issue":"2","key":"10.1016\/j.ijcard.2016.12.140_bb0085","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.semarthrit.2014.04.001","article-title":"Five-year follow-up of left ventricular diastolic function in systemic sclerosis patients: determinants of mortality and disease progression","volume":"44","author":"Faludi","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"issue":"2 Suppl. 71","key":"10.1016\/j.ijcard.2016.12.140_bb0090","first-page":"S30","article-title":"Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis","volume":"30","author":"Hinchcliff","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.ijcard.2016.12.140_bb0095","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","article-title":"Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure","volume":"12","author":"Shah","year":"2010","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.ijcard.2016.12.140_bb0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.amjcard.2015.03.055","article-title":"Galectin-3 in atrial fibrillation: a novel marker of atrial remodeling or just bystander?","volume":"116","author":"Kornej","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.12.140_bb0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ahj.2014.02.009","article-title":"Galectin 3 and incident atrial fibrillation in the community","volume":"167","author":"Ho","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.12.140_bb0110","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijcard.2015.08.099","article-title":"Clinical significance of plasma galectin-3 in patients with coronary artery disease","volume":"201","author":"Kusaka","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.12.140_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cca.2015.03.033","article-title":"Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases","volume":"445","author":"Mueller","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.ijcard.2016.12.140_bb0120","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/eurjhf\/hft077","article-title":"Galectin-3 in heart failure with preserved ejection fraction","volume":"15","author":"de Boer","year":"2013","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.ijcard.2016.12.140_bb0125","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"14","key":"10.1016\/j.ijcard.2016.12.140_bb0130","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2016.12.140_bb0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study","volume":"5","author":"Felker","year":"2012","journal-title":"Circ. Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731632099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731632099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T09:50:27Z","timestamp":1536141027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731632099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":27,"alternative-id":["S016752731632099X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.12.140","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 is an independent predictor of survival in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.12.140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}